Somewhat Positive Media Coverage Somewhat Unlikely to Affect Lumenis (LMNS) Share Price
News articles about Lumenis (NASDAQ:LMNS) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lumenis earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 47.3527166541505 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-lumenis-lmns-share-price/1762003.html.
Lumenis Company Profile
Lumenis Ltd. (Lumenis) is a provider of energy-based, minimally invasive clinical solutions. The Company operates through three segments: surgical, ophthalmic and aesthetic. The Company offers energy-based solutions for medically necessary and elective procedures, primarily for the aging population. Its solutions include the holmium laser, the Lumenis Pulse 120H, used for urologic applications; the VersaPulse PowerSuite platform which uses holmium lasers for urologic applications; the M22 multi-energy, a multi-application platform for the treatment of various skin conditions, and the Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies.
Receive News & Ratings for Lumenis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumenis and related companies with MarketBeat.com's FREE daily email newsletter.